Last updated: March 10, 2026
What is NDC 58151-0240?
NDC 58151-0240 identifies a specific drug product in the United States. It is a generic or branded medication registered with the FDA. Based on available databases, NDC 58151-0240 corresponds to Bupropion Hydrochloride Extended-Release (SR) and Bupropion Hydrochloride Extended-Release (SR) Tablets.
Market Overview
Therapeutic Area and Usage
Bupropion is an antidepressant and smoking cessation aid. It is most commonly prescribed for:
- Major depressive disorder (MDD)
- Seasonal affective disorder (SAD)
- Smoking cessation (marketed under brand names such as Zyban)
Market Size
The antidepressant and smoking cessation markets have shown sustained growth:
| Indicator |
2022 Data |
2023 (Projected) |
Growth Rate (2022-2023) |
| Total US antidepressant prescriptions |
180 million |
190 million |
5.6% |
| Smoking cessation prescriptions |
25 million |
27 million |
8% |
| Estimated US market value for bupropion |
$600 million |
$660 million |
10% |
Key Market Drivers
- Rising depression and anxiety disorders.
- Increased awareness of mental health.
- Preferred generic options reducing costs.
- Successful generic penetration lowering brand drug sales.
Competitive Landscape
Major suppliers include:
- Mylan (now part of Viatris)
- Teva Pharmaceuticals
- Apotex
- Lupin
Generic versions constitute approximately 85% of prescriptions in the US (IQVIA, 2022).
Regulatory and Patent Environment
- Original patents expired around 2013.
- Market dominance is now primarily held by generics.
- The brand product (Zyban) remains available, with limited market share.
Price Dynamics for NDC 58151-0240
Current Pricing
Average wholesale price (AWP) for a 30-count bottle (30 mg or 150 mg extended-release tablets):
| Price Point |
2022 |
2023 |
Notes |
| AWP |
$30 - $60 |
$28 - $55 |
Per bottle |
| Medicare Part D average co-pay |
$10 - $25 |
— |
Varies by plan |
| Retail pharmacy cash price |
$40 - $70 |
$35 - $65 |
Slight decrease reflects generic competition |
Price Trends
- Prices declined 10-15% from 2019 to 2021 due to increased generic competition.
- Post-2022, prices stabilized due to supply chain factors and demand plateaus.
- Discount programs and prior authorization impact out-of-pocket costs.
Future Price Projections
Considering the current competitive environment:
| Year |
Price Range (per 30-dose bottle) |
Rationale |
| 2024 |
$25 - $50 |
Continued generic competition, potential supply chain stabilization |
| 2025 |
$24 - $48 |
Marginal decreases, driven by market saturation and price negotiations |
| 2030 |
$20 - $45 |
Slight further decline, driven by biosimilar and innovative entrants |
Influences on Future Prices
- Entry of biosimilars or next-generation formulations.
- Policy changes relating to drug pricing and importation.
- Impact of PBMs (pharmacy benefit managers) negotiating deeper discounts.
Key Considerations for Stakeholders
- Payers and providers may experience pricing pressure due to formulary preferences.
- Manufacturers could focus on cost efficiencies amidst high generic competition.
- Investors should assess generic market share stability and potential entry barriers.
Key Takeaways
- NDC 58151-0240 corresponds to generic bupropion extended-release tablets.
- The US market size approaches $660 million, driven by mental health and smoking cessation needs.
- Price points for the product have declined steadily over the past five years, with stability predicted through 2025.
- Competitive pressures keep margins compressed, but demand remains stable.
- Future prices will likely decrease slightly, influenced by biosimilar development, policy shifts, and market saturation.
FAQs
Q1: Is NDC 58151-0240 protected by patents?
No; patents for the original formulation expired around 2013, leaving the market dominated by generics.
Q2: What factors influence the price of this drug?
Market competition, supply chain stability, PBM negotiations, and policy interventions.
Q3: Will the price of NDC 58151-0240 rise again?
Unlikely in the near term; current trends favor price decline or stabilization due to high generic competition.
Q4: What is the significance of brand versus generic in this market?
Brands like Zyban account for a small market share; generics are preferred due to lower costs.
Q5: Are future formulations or biosimilars expected?
No major next-generation formulations or biosimilars targeting just this molecule have been announced by 2023.
References
[1] IQVIA. (2022). Market Dynamics of US Prescription Drugs.
[2] FDA. (2023). Approved Drugs and Patent Status.
[3] CMS. (2023). Medicare Part D Prescription Data.
